The current SAA can serve as a tool to screen ALS patients to confirm the presence of TDP-43 seeds in the CSF and exclude patients without TDP-43 pathology such as those with SOD1 or FUS pathology. This evidence concerns the gene FUS and amyotrophic lateral sclerosis.